Cite
HARVARD Citation
Tarhini, A. et al. (2018). Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. Journal for immunotherapy of cancer. 6 (1), p. . [Online].